SCHEMBL9106682

SCHEMBL9106682

CCN1CCCC1=CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17689272 0.75 INMT (0.38) —
SCHEMBL11665467 0.71 ALDH1A1 (0.66) —
SCHEMBL11665470 0.71 ALDH1A1 (0.66) —
SCHEMBL23937863 0.70 — —
SCHEMBL12425172 0.70 — —
SCHEMBL25943300 0.69 INMT (0.37) —
Cyanide SCHEMBL30330027 0.69 INMT (0.37) —
Nitromethane SCHEMBL28152400 0.69 ALDH1A1 (0.62) —
SCHEMBL25477357 0.67 MEN1 (0.38) —
SCHEMBL17897735 0.67 MEN1 (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102985438-B As the C-28 acid amides of the modified C-3 betulinic acid derivative of the ripe inhibitor of HIV BRISTOL-MYERS SQUIBB CO. (US) 2016-05-18 — — CN disclosed
EP-2576586-B1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 — — EP disclosed
US-8802661-B2 C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-12 — — US disclosed
EP-2576586-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS Bristol-Myers Squibb Company (US) 2013-04-10 — — EP disclosed
US-20120142653-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 — — US disclosed
WO-2011153319-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-08 — — WO disclosed
Send feedback